|
US 12,234,236 B1 |
|
| GLP-1R agonist and therapeutic method thereof |
| Bin Liang, Hong Kong (CN); Jinzi Jason Wu, Hong Kong (CN); and Bailing Yang, Hong Kong (CN) |
| Assigned to Ascletis Pharma (China) Co., Limited, Hong Kong (CN) |
| Filed by Ascletis Pharma (China) Co., Limited, Hong Kong (CN) |
| Filed on Sep. 13, 2024, as Appl. No. 18/884,965. |
| Claims priority of provisional application 63/673,453, filed on Jul. 19, 2024. |
| Claims priority of provisional application 63/603,854, filed on Nov. 29, 2023. |
| Claims priority of provisional application 63/545,615, filed on Oct. 25, 2023. |
| Claims priority of provisional application 63/538,892, filed on Sep. 18, 2023. |
| Claims priority of application No. 202311189557.X (CN), filed on Sep. 14, 2023; application No. 202311371725.7 (CN), filed on Oct. 23, 2023; application No. 202311582240.2 (CN), filed on Nov. 24, 2023; application No. 202311686034.6 (CN), filed on Dec. 8, 2023; application No. 202410142451.2 (CN), filed on Jan. 31, 2024; application No. 202410202078.5 (CN), filed on Feb. 22, 2024; application No. 202410398964.X (CN), filed on Apr. 2, 2024; application No. 202410584679.7 (CN), filed on May 11, 2024; application No. 202410963587.X (CN), filed on Jul. 17, 2024; and application No. 202411237048.4 (CN), filed on Sep. 4, 2024. |
| Int. Cl. C07D 471/04 (2006.01); A61K 31/437 (2006.01); C07D 519/00 (2006.01) |
